A second shot given to trial participants six months after their first injection could offer substantial protection, Zhu Tao, CanSinoBIO‘s chief scientific officer, said in an online presentation late on Wednesday.
“A booster shot six months later led to a seven times to 10-times increase in neutralising antibody levels, so we expect in this case efficacy could reach over 90%,” Zhu said, though he cautioned more clinical trial data was needed for more precise estimates.
The company in February reported interim data that showed the shot was 68.83% effective at preventing symptomatic Covid-19 disease two weeks after vaccination but the rate fell to 65.28% after four weeks.
The February data reflected a shorter time span after the inoculation, Zhu said.
The vaccine has been approved in China, Pakistan, Hungary and Mexico.
CanSinoBIO is also planning a clinical trial in China for an inhaled version of the vaccine.